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HLA-DR4,  like  most  other  HLA-DR  specificities,  is  a  serologically defined 
public specificity present on a  number of different haplotypes.  Hapiotypes that 
share the DR4 specificity may differ considerably; polypeptide products of HLA 
class II genes in the DR and DQ regions vary among different DR4 + cells (1-4) 
and  restriction  endonuclease  fragment  length  polymorphisms  (RFLP)  identify 
nucleotide variation among different DR4 + haplotypes (5).  Polymorphic varia- 
tions within HLA class II molecules are implicated in the regulation of immune 
response, and are associated with susceptibility to a number of different diseases, 
including insulin-dependent diabetes mellitus (IDDM) and seropositive juvenile 
rheumatoid  arthritis  (IRA),  which  are  both  associated  with  HLA-DR4  (6-9). 
Using RFLP to analyze specific genotypic markers associated with HLA-DR4 in 
these two clinically disparate diseases, we have identified a specific DQ/3 variant 
highly associated  with  IDDM.  Different  DQ~ genomic patterns  were found in 
JRA, implicating different genetic elements contributing to HLA-linked disease 
susceptibility for these two diseases. 
Materials and  Methods 
Patient Selection and HLA Typing.  JRA patients were chosen from those attending the 
Arthritis Clinic at Children's Orthopedic Hospital and Medical Center, Seattle, WA. The 
diagnosis  of seropositive JRA  was  made  using previously described criteria  (8).  HLA 
typing of these patients has been previously reported (9); all patients used in this report 
are homozygous for HLA-DR4. IDDM patients were selected from those attending the 
Diabetes Center at Pacific Medical Center, Seattle, WA, and fulfill the criteria for juvenile 
onset insulin-dependent diabetes. We selected 17 DR4  ÷ patients for this study. All of the 
DR4  + haplotypes were positive for HLA-DQw3. However, no specific HLA-B antigens 
or class III markers suggesting preferred extended haplotypes were observed. 
7  Analysis ofGenomic DNA.  DNA was obtained from 4 ×  I 0  peripheral blood [eukocytes 
either freshly drawn or following in vitro culture for 7 d in the presence of PHA and IL- 
2.  For some studies,  EBV-transformed B lymphoblastoid lines prepared from patients' 
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lymphocytes were used. After endonuclease digestion for 18 h at 37 °C (Barn HI) or 65 °C 
(Taq I), DNA digests were precipitated  with ethanol and resuspended in 10 mM Tris,  1 
mM EDTA, pH 7.6. Digested DNA was loaded at 12 ug per lane on a 0.7% agarose gel, 
and electrophoresed  at 30  V for 18 h. After electrophoresis,  gels were denatured and 
neutralized  before  transfer to nitrocellulose (Schleicher & Schuell, Inc., Keene, NH) by 
the  method of Southern  (10). After transfer,  filters  were  baked  for  18  h  at  80°C, 
prehybridized  at  42°C,  and  hybridized  with  nick-translated,  P-32-1abeled DQ  cDNA 
probes. The DQ/3 cDNA probe (11 ) and the DQa cDNA probe (12) were used as previously 
described (5). After 48 h of hybridization at 42°C, blots were washed at 60°C in 1.5 mM 
NaCl, 0.015 mM sodium citrate, and 0.1% SDS three times for 20 min each. Autoradi- 
ographs are shown after exposure of the gels to Kodak XAR-5 film for 2-4 d. 
Results and Discussion 
In previous studies, we have identified specific nucleotide variation within the 
DQfl genomic region which identifies two allelic DQ/3 variants on HLA-DR4  + 
haplotypes,  DQ3.1  and  DQ3.2  (13).  A  number  of restriction  endonucleases, 
including Bam HI, Hind lII, Taq I, Pvu II, Xba I, and Sst I, generate different 
cleavage fragments on genomic DNA from these DQw3 +, DR4 + individuals. DQ- 
reactive mAb 9w790, which defines a variant of DQw3 designated TA 10, reacts 
with  cells  carrying  the  DQ3.1  allelic  variant,  but  not  the  DQ3.2  (13),  and 
restriction  mapping  of genomic  DNA  with  a  DQ/3 synthetic oligonucleotide 
probe (14)  confirms the assignment of the DQ/3 variant RFLP to the DQ/32 (or 
DC/3) locus. 
We used these specific genotypic markers to investigate the genomic basis of 
the association of DR4  with  IDDM  and JRA.  IDDM  is  highly associated with 
DR4 +, Dw4 + phenotypes, and the risk of disease is greatest in DR3/4 and Dw3/ 
Dw4 heterozygous individuals (6-7). DNA from 17 patients was analyzed for the 
presence of specific DQ variants using RFLP analysis with DQ¢3 cDNA probes. 
As shown in  Fig.  1,  panel IA,  using the enzyme Barn  HI, polymorphic bands 
representing the two DQ/3 alleles associated with DQw3 are apparent among ten 
representative patients.  A  12.0-kb  band  identifies the  DQ3.2  allele,  which  is 
present in all but one of the diabetic patients (D12).  In contrast, the alternate 
allele DQ3.1  is represented by a pair of bands at 6.9 kb and 3.7 kb (13). A  10.2- 
kb band is  invariant in both  DR3- and  DR4-related haplotypes, and a  6.9-kb 
band is invariant among the DR3-related haplotypes. Because of the DR3-related 
invariant 6.9-kb  band,  we must focus on the  3.7-kb band to determine which 
patients express this allele. All but  1 of the  17 patients studied so far show the 
DQ3.2 allele, thus showing the predominant expression of the DQ3.2 allele and 
the very rare expression of the DQ3.1 allele among these DR4  + diabetics. 
We contrasted these  results with a  similar analysis of patients with another 
DR4-related disease, seropositive juvenile rheumatoid arthritis (.IRA). We have 
previously reported  that  the  strong  DR4  association  with  this  form  of JRA 
represents two haplotypes, DR4,Dw4 and DR4,Dw 14; many of the JRA patients 
are heterozygous for these two DR4 + haplotypes (9).  Panel IIA of Fig.  1 shows 
DQ/3 cDNA hybridization of Barn  HI digested genomic DNA from 10 of these 
patients. In cases in which a DR4+,Dwl 4 + haplotype is expressed, a concomitant 
DQ3.2 allele is also present,  consistent with our previous observation that the 
3.2 DQ¢3 variant is in linkage disequilibrium with the Dw 14 haplotype (13).  The 
expression  of  DQ¢~ variants  on  the  DR4+,Dw4  +  haplotype  permits  a  direct FIGURE  1.  (I) Genomic DNA from patients with either IDDM orJRA (B) digested with Bam 
HI endonuclease and probed  with a  DO~ cDNA probe.  DR types of the patients are: lanes 
1-8,  DR3,4;  lane 9,  DR4,X;  lane  10,  DR4;  lanes  11-20,  DR4,4.  (H) Genomic  DNA from 
patients with either IDDM (A) orJRA (B) digested with Taq I and probed with a DQa probe. 
Again, all  IDDM patients  are  DR3,4,  except in lane 3  (DR4,X) and  lane 4  (DR4);  all JRA 
patients are DR4,4. (III) Genomic DNA from IDDM patients and siblings from two families, 
digested with  Barn  HI and  probed  with  DQ/3. The  left side represents  five siblings from a 
single family with the haplotypes as shown, a: A1, B8, DR3, b: A26, B15, DR3; c: Aw24, B40, 
DR4; and d:  Aw30,  Bw35,  DR4.  The right  side shows three  siblings from a  second family. 
Haplotype  a:  A2,  B15,  DR4;  b:  A10,  B27,  DR1,  d:  A3,  B7,  DR5;  and  c:  A3,  B8,  DR3. 
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comparison  with  the  analogous  IDDM  hapiotype.  8  of  12  Dw4  +  haplotypes 
among the JRA patients are associated with the DQ3.1  variant characterized by 
3.7-kb and 6.9-kb Barn HI hybridizing fragments.  This is in marked contrast to 
the  distribution  in  the  DR4+,Dw4  ÷ IDDM  population,  in  which an  extremely 
high  (>90%) incidence of HLA DQ3.2  is observed. The  HLA DQ3.2  marker 
occurs in association with a wide variety of HLA-B and class III alleles, as noted 
in Materials and Methods. Therefore this DQ polymorphism is not a marker for 
a  single extended haplotype associated with  DR4. This conclusion is consistent 
with reports of associated haplotypes in IDDM in which DR3 + extended haplo- 
types frequently occur, but most DR4  + haplotypes are "nonextended"  (15). 
When additional  restriction  fragment analyses are performed, genotypic dif- 
ferences between  IDDM  and JRA haplotypes can  be shown  for  DQa as  well. 
Panel//shows hybridization with DQo~ cDNA probes of Taq I--digested cellular 
DNA from both groups of patients.  A  5.8-kb and a 4.8-kb hybridizing band are 
invariant bands associated with DR4 and DR3 haplotypes, respectively. Bands at 
2.2 kb and 2.1  kb are polymorphic, and appear to be allelic to each other. The 
expression of these RFLP differ in the two patient  groups: Only five of the  17 
diabetics  tested  (29%)  are  positive  for  the  2.1-kb  band,  although  100%  are 
positive for the 2.2-kb band. In contrast,  11 of 12JRA patients (92%) are positive 
for the 2.1-kb band while 8 of 12 (67%) are positive for the 2.2-kb band. 
The  use  of specific  genotypic  markers,  such  as  the  DQ/3  and  DQ~  allelic 
variants described here, permits the molecular characterization of phenotypically 
similar  HLA  haplotypes  associated  with  distinct  diseases.  Our  results,  in  the 
examples  cited  above,  indicate  that  while  DR4+,Dw4  +  haplotypes  in  IDDM 
patients  consistently  show  a  particular  DQ~  allelic  variant,  the  analogous 
DR4+,Dw4  + haplotypes in  the JRA patients do not.  Previous reports analyzing 
RFLP differences in IDDM have noted the decrease of a  Barn HI 3.7-kb RFLP 
(16,  17);  we can now attribute this observation to the prevalence of the DQ3.2 
allele  in  IDDM.  In  one  report,  RFLP  differed  between  IDDM  patients  and 
controls,  including their  normal  healthy siblings (18).  However, these previous 
studies  did  not  match  the  test  groups  for  haplotype  identity.  We  therefore 
evaluated hapiotype-matched siblings from two IDDM families, shown in Panel 
III,  again  using Bam HI digested cellular DNA probed with DQ/3 cDNA. None 
of the healthy family members displays a  DQ3.1-associated, 3.7-kb band.  How- 
ever,  all  of the  DR4  + siblings  display  the  12.0-kb  band  characteristic  of the 
IDDM-associated  DQ3.2  allele,  whether  or  not  they express  clinical  diabetes. 
Thus,  both affected and  healthy individuals can carry the same haplotypes and 
specific allelic variants,  which  can  indicate an  increased  risk of IDDM but are 
not in fact disease specific. 
We chose to compare IDDM andJRA because both are highly associated with 
HLA-DR4, and both are even more highly correlated with a heterozygous state, 
HLA-DR3,Dw3/DR4,Dw4 in  IDDM  (6,  7) and  HLA-DR4,Dw4/DR4,Dwl4 in 
seropositive JRA (9).  This heterozygous predisposition might indicate the possi- 
bility of two gene  effects or gene  complementation  within  the  class  II  region 
contributing  to  a  mechanism  for  increased  susceptibility.  There  are  marked 
differences between IDDM and JRA, most notably the difference in end organ 
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within the HLA DQ region potentially may contribute to such clinical differences, 
since variations in class  II molecules are  implicated in a  number of important 
immunoregulatory mechanisms, including immune cell activation, intercellular 
communication, and target specificity. 
Summary 
HLA-DR4,  Dw4-associated haplotypes associated with IDDM and JRA were 
compared using genomic DNA restriction fragment analysis to distinguish among 
DQ/3 and 0~ alleles linked to DR4. DQ/3 polymorphisms that subdivide the HLA- 
DQw3 specificity into DQ3.1  and 3.2 alleles were identified. More than 90% of 
DR4 + IDDM  patients express  one of these alleles,  DQ3.2;  restriction  enzyme 
mapping indicates that the presence of this allele also accounts for the genomic 
fragment patterns previously reported in  IDDM.  Furthermore, haplo-identical 
siblings  of  DQ3.2  IDDM  patients  also  carry  the  DQ3.2  allele,  regardless  of 
clinical presentation. In contrast, DR4 + JRA patients show no allelic preference 
at  DQ~,  implicating different  HLA  genetic  contributions  in  these  two  DR4- 
associated diseases. 
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